Benlysta

• Healthcare
• Pharma & Biotech
• Spain
• United Kingdom

GSK: Benlysta plus standard of care prolonged control of disease activity in patients with active systemic lupus erythematosus (SLE)

Final efficacy and safety results from phase II continuation study Madrid, Spain and London, UK, 19-Jun-2017 — /EuropaWire/ — GSK today…